EricKeithRowinskyMD

Breast Cancer, Gastrointestinal Cancer, Clinical Pharmacology

President, Inspirna Inc; Consulting CMO, Biocity, Inc.; Board of Directors, Biogen, Purple Bio, Verastem, Fortress Bio, Inspirna

Join to view full profile

Dr. Rowinsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rowinsky's full profile

Already have an account?

Office
Inspirna, Inc.
Boca Raton, FL 33432
Phone+1 908-883-0647

Summary

Focus is on the development of cancer therapeutics and novel treatments in other therapeutic indications in the biotechnology industry. Develop developmental strategies for novel therapeutics and incorporate such into corporate strategies. Asset and corporate evaluations for biopharma and investors.

Education & Training

Vanderbilt University School of MedicineClass of 1981

Certifications & Licensure

TX State Medical License 1996 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bizelesin in Treating Patients With Advanced Cancer Start of enrollment: 1997 Aug 01
Completed
Phase 1
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Start of enrollment: 1998 Apr 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 1
CCI-779 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 Jan 01
Completed
Phase 1
Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Nov 01
Completed
Phase 1
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer Start of enrollment: 1998 Nov 01
Completed
Phase 2
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma Start of enrollment: 2001 Mar 01
Completed
Phase 2
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2 Start of enrollment: 2017 Jul 13
Suspended
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma Start of enrollment: 2019 Jul 29
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

63 citations
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K. Rowinsky, Agne Paner, Jesus G. Berdeja, Claudia E. Paba-Prada, Parameswaran Venugopal
Investigational New Drugs. 2020-03-03
45 citations
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Todd A. Fehniger, Jeffrey S. Miller, Robert K. Stuart, Sarah Cooley, Amandeep Salhotra
Biology of Blood and Marrow Transplantation. 2018-08-01
310 citations
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco, Benjamin N. Ostendorf, Bernardo S. Reis
Cell. 2018-02-08

Press Mentions

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid MalignanciesDecember 6th, 2021
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of DirectorsMay 19th, 2021
Shanghai Genechem Co., Ltd. (Genechem) Announces Appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory Board, and Abstract Presentation at AACR 2021 on Claudin 6 Ab and K-ras TCR-TApril 8th, 2021
Join now to see all

Grant Support

Phase II Pharmacologic/Biologic Study Of ThalidomideNational Center For Research Resources2004
PH I Study Of BMS-247550 In PTS With Advanced NeoplasmsNational Center For Research Resources2004
PH I Pharmacokinetics Of Nsc-655649/Cisplatin/G-CsfNational Center For Research Resources2004
Phase I Clinical Trials Of Anti-Cancer AgentsNational Cancer Institute2003
ERBB1 And ERBB2 Blockade In Advanced Breast CancerNational Cancer Institute2003
Phase II Trial Of DX 8951f In Hepatocellular CarcinomaNational Center For Research Resources2000–2002
Pharmacokinetic Trial Of Weekly Docetaxel In Solid TumorNational Center For Research Resources2000–2002
Pharmacokinetic Study Of Troxacitabine And CisplatinNational Center For Research Resources2000–2002
IV Dx8951f In Patients With Advanced Solid TumorsNational Center For Research Resources2000–2002
Intoplicine Pharmacokinetics--Continuous 5 Day 4 Wk DoseNational Center For Research Resources2000–2002
Combination Paclitaxel/L778,123 In Solid TumorsNational Center For Research Resources2000–2002
Trial Of Zeneca ZD9331 Given As An Oral TabletNational Center For Research Resources1999–2002
Sch52365: Phase I Study Of Cyclic Oral AdministrationNational Center For Research Resources1999–2002
Phase I Trial Of LY231514 W/ IrinotecanNational Center For Research Resources1999–2002
Phase I Trial Of LY231514 In Patients W/ Varying Degrees Of Renal FunctionNational Center For Research Resources1999–2002
Phase I Trial Of Bizelesin Using Single Bolus Infusion Every 28 DaysNational Center For Research Resources1999–2002
Phase I Study Of CP 358,774 In Subjects W/ Advanced Solid TumorsNational Center For Research Resources1999–2002
Phase I Study Of CCI 779 In Patients W/ Advanced Solid TumorsNational Center For Research Resources1999–2002
Phase I Study Of Bms 184476 In Patients W/ Advanced MalignanciesNational Center For Research Resources1999–2002
7 Day Continuous Infusion Of L778123 In Recurrent MalignanciesNational Center For Research Resources1999–2002
Phase I Pharmacokinetic Study Of Bch 4556National Center For Research Resources1998–2002
Phase I Dose Escalation Trial Of Zeneca ZD9331National Center For Research Resources1998–2002
Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1998–2002
Phase I Study Of IV Dx88951f Given Daily For 5 Days Every 3 WeeksNational Center For Research Resources1999–2000
Phase I Study Of Combined 776c85 &5 FU Tablet &5 FU TabletsNational Center For Research Resources1999–2000
Phase I Study Of Docetaxel And Doxorubicin Combination ChemotherapyNational Center For Research Resources1998–1999
Absorption, Metabolism, Excretion Of SCH 52365 (Temozolomide)In Advanced CancerNational Center For Research Resources1997
Human Metabolism Of TaxolNational Cancer Institute1991–1993